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1  | INTRODUC TION
Hepatocellular adenoma (HCA) is a benign liver tumour that may be 
complicated by haemorrhage or malignant transformation to hepa-
tocellular carcinoma (HCC). Risk factors for HCA include long-term 
use of the oral contraceptive pill (OC),1,2 obesity and the metabolic 
syndrome,3-5 androgen consumption 6 and genetic disorders such as 
MODY-3 and glycogen storage disease.7-9 Two clinical practice guide-
lines have been issued on the management of benign liver tumours: the 
first from the American College of Gastroenterology (ACG, dating from 
2014) and the second from the European Association for the Study of 
the Liver (EASL, dating from 2016).10,11 Since the publication of these 
guidelines, much progress has been made in the field of hepatocellular 
adenoma. In this review, we describe the major recent advances in this 
field, including epidemiology, diagnosis (imaging and pathology), prog-
nosis and treatment and discuss the implications in clinical practice.
2  | EPIDEMIOLOGY
For a long time, epidemiological data on HCA were severely outdated. 
In 1979, the annual incidence rate was estimated at 3-4 per 100.000 
women per year for long-term OC users, as compared to 0.1 per 100.000 
women per year for non-long-term users.12 The next study concerning 
 
Received: 5 March 2020  |  Revised: 30 April 2020  |  Accepted: 21 May 2020
DOI: 10.1111/liv.14547  
R E V I E W
New insights in the management of Hepatocellular Adenoma
Anne J. Klompenhouwer1  |   Robert A. de Man2 |   Marco Dioguardi Burgio3,4 |   
Valerie Vilgrain3,4 |   Jessica Zucman-Rossi5,6 |   Jan N. M. Ijzermans1
This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2020 The Authors. Liver International published by John Wiley & Sons Ltd
1Department of Surgery, Erasmus MC 
University Medical Center, Rotterdam, the 
Netherlands
2Department of Gastroenterology and 
Hepatology, Erasmus MC University Medical 
Center, Rotterdam, the Netherlands
3Department of Radiology, Hauts-de-Seine, 
University Hospitals Paris Nord Val de Seine, 
Beaujon, APHP, Clichy, France
4Centre de Recherche sur l'inflammation 
(CRI), INSERM U1149, et Université de Paris, 
Paris, France
5Centre de Recherche des Cordeliers, 
Sorbonne Université, INSERM, Université de 
Paris, Paris, France
6Oncology Department, APHP, Hôpital 
européen Georges Pompidou, Paris, France
Correspondence
Jan N. M. Ijzermans, Department of Surgery, 
Erasmus MC University Medical Center, Dr. 
Molewaterplein 40, 3015 GD Rotterdam, 
the Netherlands.
Email: j.ijzermans@erasmusmc.nl
Handling Editor: Alejando Forner
Abstract
Hepatocellular adenoma (HCA) are benign liver tumours that may be compli-
cated by haemorrhage or malignant transformation to hepatocellular carcinoma. 
Epidemiological data are fairly outdated, but it is likely to assume that the incidence 
has increased over the past decades as HCA are more often incidentally found due to 
the more widespread use of imaging techniques and the increased incidence of obe-
sity. Various molecular subgroups have been described. Each of these molecular sub-
groups are defined by specific gene mutations and pathway activations. Additionally, 
they are all related to specific risk factors and show a various biological behaviour. 
These molecular subgroups may be identified using immunohistochemistry and 
molecular characterization. Contrast-enhanced MRI is the recommended imaging 
modality to analyse patients with suspected hepatocellular adenoma allowing to de-
termine the subtype in up to 80%. Surgical resection remains to be the golden stand-
ard in treating HCA, although resection is deemed unnecessary in a large number of 
cases, as studies have shown that the majority of HCA will regress over time without 
complications such as haemorrhage or malignant transformation occurring. It is pref-
erable to treat patients with suspected HCA in high volume centres with combined 
expertise of liver surgeons, hepatologists, radiologists and (molecular) pathologists.
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the epidemiology of HCA was not published until 2017. This was a nation-
wide registry-based cohort study from Denmark.13 The authors investi-
gated the incidence of hepatocellular adenoma and found a standardized 
incidence rate of biopsy-confirmed adenomas of 0.07 per 100.000 popu-
lation per year (0.02 per 100.000 for men and 0.13 for women). The true 
incidence rate, however, will probably be higher as only patients with 
biopsy-confirmed HCA were included in this study. It is likely to assume 
that the incidence has increased since 1979 as HCA are more often in-
cidentally found due to the more widespread use of imaging techniques. 
Additionally, the obesity epidemic may have led to an increase in the 
incidence of HCA.3,4,14 Epidemiological data on HCA from Europe and 
the United States have seldom been compared to data from continents 
where both the use of oral contraceptives and the incidence of obesity 
is lower. A recent single-centre study from Taiwan showed that the local 
incidence of HCA increased over the last decade and that the clinical fea-
tures differ from those reported in Europe and the United States.15 For in-
stance, they found a male predominance in their cohort. It would be very 
interesting to further explore these differences in epidemiological data.
3  | PATHOLOGY
HCA results from a monoclonal benign proliferation of hepatocytes. 
Usually, tumour hepatocytes in HCA look similar to normal hepato-
cytes. During the last 20 years, genomics analyses of large series of 
hepatocellular adenomas enabled to progressively identify six major 
molecular subgroups and additional mixed subtypes of HCA. Each of 
these molecular subgroups are defined by specific gene mutations 
and pathway activations. They are all related to specific risk factors 
and show a various biological behaviour.
3.1 | HNF1A inactivated HCA (H-HCA)
The first molecular subgroup accounts for 30% to 40% of adenomas 
and is defined by a mutation inactivating HNF1A, a gene coding for 
Hepatocyte Nuclear Factor 1 Alpha. This is a transcription factor es-
sential for the differentiation of hepatocytes.16 HNF1A inactivation 
in hepatocytes leads to several metabolic alterations with an acti-
vation of lipogenesis.17,18 As a result, HNF1A inactivated adenomas 
accumulate lipids in tumour hepatocytes leading to a characteristic 
homogeneous steatotic phenotype at histology, without inflam-
matory infiltrates. Multiple H-HCA is frequent in patients, and it 
is often referred to liver adenomatosis when more than 10 H-HCA 
are identified in the liver. In rare cases, familial liver adenomatosis 
has been described related to a Maturity Onset Diabetes type 3 
(MODY3) with a transmitted HNF1A germline mutation.7,19
3.2 | Inflammatory HCA (I-HCA)
I-HCA is the most frequent subtype (40%-50% of the cases), de-
fined by the activation of STAT3, a major transcription factor of 
inflammation. In I-HCA, an activating mutation of one the fac-
tors of the IL6/STAT3 signalling pathway is identified targeting ei-
ther IL6ST, FRK, STAT3, JAK1, GNAS1 or ROS1.20-22 Each of these 
gene activations leads to the overexpression of the proteins of the 
acute inflammatory phase including SAA (serum amyloid protein) 
and CRP (C-reactive protein), by tumour hepatocytes. At histol-
ogy, I-HCAs show marked inflammatory infiltrates together with 
a high vascularization combining small arteries and telangiectasia. 
Immunohistochemistry shows a typical staining of tumour hepato-
cytes using antibodies against SAA or CRP. I-HCA is frequently 
identified in obese patients and can be associated with alcohol 
intake. They are also frequent in patients with vascular liver dis-
eases and finally multiple I-HCA and liver I-HCA adenomatosis are 
described.19,21
3.3 | Beta-catenin activated HCA (b-HCA)
ß-catenin is an important oncogene in the liver. Two types of muta-
tions in the CTNNB1 gene have been identified in HCA, leading to 
an activation of ß-catenin.
Mutations or deletions at exon 3 of CTNNB1 are identified in 
10 to 15% of HCA (bex3HCA). These alterations are well-known on-
cogenic mutations, that lead, in the vast majority of the cases, to a 
high activation of the WNT/ß-catenin pathway.23,24 The histological 
phenotype of the tumour usually combines tumour cholestasis, cy-
tological atypia and tumour dysplasia. Using immunohistochemistry, 
a homogeneous overexpression of GS (glutamine synthetase) is de-
tected with a nuclear accumulation of ß-catenin in some cases. This 
subtype is frequently associated with a malignant transformation to 
hepatocellular carcinoma, particularly in males.21,23
Key points
• Epidemiological data on HCA are fairly outdated but it 
is likely to assume that the incidence has increased over 
the past decades as HCA are more often incidentally 
found due to the more widespread use of imaging tech-
niques and the increased incidence of obesity.
• Various molecular subgroups of HCA have been de-
scribed with varying biological behaviour.
• These molecular subgroups may be identified using 
contrast-enhanced MRI, immunohistochemistry and 
molecular characterization.
• Surgical resection remains to be the golden standard in 
treating HCA, although resection is deemed unneces-
sary in a large number of cases.
• As HCA may be considered a rare disease, it is prefer-
able to treat patients with suspected HCA in high vol-
ume centres with combined expertise of liver surgeons, 
hepatologists, radiologists and (molecular) pathologists.
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Around 7 to 10% of HCA show atypical hotspot mutation at exon 
7 or 8 of CTNNB1 (bex7,8HCA).25 These mutations lead to a faint 
ß-catenin activation, and immunohistochemistry show only a het-
erogeneous and weak expression of glutamine synthetase without 
nuclear ß-catenin. Interestingly, malignant transformation to hepa-
tocellular carcinoma has been described far less in CTNNB1 muta-
tions in exon 7 or 8 as compared to exon 3.26 Overall, b-HCA is not 
steatotic and do not show inflammatory infiltrates.21,25
3.4 | Sonic hedgehog activated HCA (sh-HCA)
In 5% of all hepatocellular adenomas, an activation of GLI1, a major 
transcription factor of the sonic hedgehog pathway, is observed. As 
a consequence, sh-HCA shows an overexpression of specific genes 
such as PTGDS (Prostaglandin D2 Synthase) that can be demon-
strated by immunohistochemistry.21 Sh-HCA is frequently identified 
in obese patients and they are associated with a higher risk of bleed-
ing. However, currently no other specific histological features are 
associated with this subtype.
3.5 | Mixed beta-catenin-inflammatory adenoma 
(b-IHCA)
Mixed molecular subclasses showing both inflammatory and ß-
catenin activation and resulting in bex3IHCA or b-ex7,8IHCA are ob-
served in around 10% of the cases. Their histological pattern results 
from the combination of each subtype. In contrast, H-HCA or sh-
HCA is almost never mixed with another molecular subtype.21
F I G U R E  1   Overview of HCA subtypes
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3.6 | Unclassified HCA (U-HCA)
Overall, in less than 7%, HCA remain unclassified. They do not show 
specific histological features. An overview of all molecular subtypes, 
risk factors and biological behaviour is given in Figure 1.
4  | IMAGING
As suggested by the 2016 EASL guidelines on the management of 
benign liver tumours, contrast enhanced MRI is the recommended 
imaging modality to analyse patients with suspected HCA allowing 
to determine the subtype in up to 80%.11 Additionally, MRI is use-
ful to differentiate HCA from focal nodular hyperplasia (FNH) using 
the combination of classical diagnostic criteria for FNH and lesion 
behaviour on hepatobiliary phase MRI using liver-specific contrast 
agents.27 Contrast-enhanced CT also allows the visualization of le-
sion enhancement patterns and dilatation of intratumoral sinusoids, 
without any additional information over MRI. Contrast-enhanced ul-
trasound can be performed in addition to MRI to differentiate small 
(<3 cm) HCA from FNH in doubtful cases, although it has a limited 
value in differentiating among different HCA subtypes.11,28,29
4.1 | HNF1A inactivated HCA
Most of H-HCA is characterized microscopically by the presence 
of fat. The resulting diffuse and homogeneous drop of signal on 
opposed-phase T1-weighted MR images (Figure 2) has a very high 
specificity (89%-100%) and high sensitivity (87%-91%) for the diag-
nosis of H-HCA.30,31 Other imaging features characterizing H-HCA 
include mild hyper-enhancement on hepatic arterial phase, followed 
by washout on later phases (Figure 2) and hypointensity on the hepa-
tobiliary phase.
4.2 | Inflammatory HCA
I-HCA is characterized on MRI by strong hyperintensity on T2 im-
ages (diffuse or peripheral, “atoll sign”), and persistent enhancement 
on portal and delayed phases using extracellular MR contrast agents. 
Combination of these signs has a high specificity (88%-100%) for 
classifying inflammatory HCA 30-32 (Figure 3).
Use of gadoxetic acid as liver-specific MRI contrast agent may 
modify the typical persistent enhancement. During transitional 
phase (3-5 minutes) vascular structures including dilated sinusoids 
within the tumour appear hypointense due to the rapid clearance 
of the gadoxetic acid from the vascular pool.33 A study from Ba-
Ssalamah et al showed that while 95% of inflammatory HCA pre-
sented with persistent enhancement on the portal phase after 
gadoxetic acid injection, only 48% showed persistent enhancement 
during the transitional phase.34 Hence persistent enhancement 
should be only evaluated on portal venous phase when gadoxetic 
acid is used as contrast agent for MRI, while lesion hypointensity 
during transitional phase should not exclude the diagnosis of I-HCA.
In the hepatobiliary phase, most I-HCA are hypointense 
(Figure 3). Nevertheless, around one third of them show an iso- or 
hyperintense signal relative to the liver.34-36 As I-HCA frequently 
F I G U R E  2   H-HCA in a 23-year-old 
woman. MR images show a large lesion 
in the right liver lobe. The MR shows the 
presence of diffuse fat deposition within 
the lesion (drop of the signal on opposed-
phase T1-weighted image B—if compared 
to in phase image—A). The lesion slightly 
enhances on hepatic arterial phase (C) and 
shows washout on portal venous phase 
(D)
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develop in a steatotic liver and show spontaneous T1 hyperintensity, 
the reduced intensity of the background parenchyma (due to ste-
atosis) on fat saturated sequences combined with their spontaneous 
hyperintensity on T1 can explain the lesion iso-hyperintensity in the 
hepatobiliary phase.37 Therefore, a quantitative approach based on 
liver-to-lesion contrast enhancement ratio (LLCER), helps identify 
the real contrast uptake in the hepatobiliary phase.35 Interestingly, in 
a recent study, 100% of I-HCA had a negative (<0%) LLCER whereas 
86% of beta-catenin activated HCA (β-HCA) had a positive (>0%) 
LLCER.37 The latter may be explained by the conserved expression 
of OATP (organic-anion-transporting polypeptide) in the b-HCA.
4.3 | Beta-catenin activated HCA—Sonic hedgehog 
activated HCA—Unclassified HCA
At present, it is not possible to accurately differentiate b-HCA, sh-
HCA and U-HCA subtypes with imaging. Differently from I-HCA, 
b-HCA develop mostly in non steatotic livers.37 b-HCA have initially 
been reported to be heterogeneous on all MR sequences,30 some-
times with necrotic portions but without fat components, typi-
cally hypervascular with variable washout appearance.30,34 These 
features are not sufficiently accurate. Practically, the diagnosis of 
b-HCA should be considered when a lesion that does not meet imag-
ing criteria of focal nodular hyperplasia shows iso- to hyperintensity 
on the hepatobiliary phase or a positive LLCER between unenhanced 
and hepatobiliary phase (Figure 4), a heterogeneous appearance on 
T1-weighted images and a vague defined scar or heterogeneous ap-
pearance on T2-weighted images.34,36-39 A recent study also sug-
gested the potential added value of low ADC value for the diagnosis 
of b-HCA.40 These preliminary data need to be validated in larger 
cohorts. Moreover an evident limitation of these studies is the ab-
sence of distinction between exon 3 and exon 7,8 b-HCA subtypes.
The combined form of I-HCA and exon 3 or exon 7,8 b-HCA (bex-
3IHCA or bex7,8IHCA), are likely to show the same imaging appear-
ance as I-HCA.30,41 Therefore, differentiating between a pure I-HCA 
and a b-IHCA is a new diagnostic challenge in imaging.
Finally, sh-HCA and U-HCA do not show specific imaging fea-
tures and are often not distinguishable from hepatocellular carci-
noma. Sh-HCA could be expected to present with haemorrhagic 
components at imaging,21 but this still needs to be explored further.
5  | BIOPSY
With the continuing knowledge of HCA subtypes and their varying 
biological behaviour, subtype determination is increasingly impor-
tant. At this moment only H-HCA and I-HCA can be identified relia-
bly based on contrast enhanced MRI. Given the low risk of malignant 
transformation and the high sensitivity of MRI in correctly diagnos-
ing H-HCA, these lesions may not have to be biopsied. However, 
when there is doubt about the subtype on contrast-enhanced MRI, 
a biopsy should be performed in the lesion. Additionally, as I-HCA 
cannot be differentiated from bex3IHCA or bex7,8IHCA on imaging 
F I G U R E  3   I-HCA in a 26-year-old woman. The lesion is bright on T2-weighted image (A), is slightly hyperintense on fat-suppressed T1-
weighted image (B), shows intense and heterogeneous enhancement on arterial phase (C), with persistent enhancement on portal venous 
phase after gadobenate dimeglumine injection (D). The lesion is hypointense on hepatobiliary phase (E—120 minutes)
(A) (B) (C) (D) (E)
F I G U R E  4   bex3HCA in a 22-year-old woman. The lesion of the segment IV of the liver (arrows) is hyperintense with a heterogeneous 
appearance on T2-weighted image (A). The lesion is slightly hypointense on fat-suppressed T1-weighted image (B), slightly and 
heterogeneously hyperenhanced on arterial phase (C) and heterogeneously isointense on portal venous phase (D) after gadobenate 
dimeglumine injection. The lesion is visually hypointense on hepatobiliary phase (E—120 minutes) if compared to the background liver. A 
quantitative approach using LLCER helps point out the contrast uptake on hepatobiliary phase (LLCER measured at 18.6%). Diagnosis of 
bex3HCA activated hepatocellular adenoma was confirmed after resection
(A) (B) (C) (D) (E)
6  |     KLOMPENHOUWER Et aL.
yet, biopsy may also be performed in case of an I-HCA to determine 
whether the lesion has an additional exon 3 or exon 7,8 mutation. 
The value of biopsy to identify HCA subtypes at risk for malignancy 
or haemorrhage is becoming a pivotal step in the management of 
this rare disease.
6  | FOLLOW-UP OF HC A -  WHEN TO 
TRE AT?
Treatment of HCA should be reserved for patients with a high risk of 
haemorrhage and development of HCC. Subgroups at risk are men 
with HCA, patients with β-(I)HCA, and patients with HCA showing 
progressive growth.13,21,42 Additionally, the 2016 EASL guideline 
advised to implement lifestyle changes for all female patients with 
HCA, irrespective of baseline diameter.11 The most important life-
style change is cessation of oral contraceptives, as it has been shown 
even in the 1970s that this can lead to regression of HCA.43 In the 
past decade, several studies have also shown that weight loss may 
lead to regression of HCA in obese patients.4,44 The EASL guideline 
states to perform a surgical resection if HCA exceed 5 centimetres 
six months after implementation of these lifestyle changes, given 
the higher risk of complications in HCA > 5cm.42,45 Two recent stud-
ies however advocate to await the effect of cessation of oral contra-
ceptives for a longer period of time (at least 12 months and longer 
for larger HCA) as the majority of HCA will regress over time and no 
complications occurred during follow up in these cohorts.46,47
The chance of regression of HCA to <5 cm appears to be lower in 
H-HCA as compared to I-HCA.47 Interestingly, a recent study even 
showed that H-HCA have a higher rate of progression from <5 cm 
to >5 cm as compared to I-HCA, despite a lower and shorter oral 
contraceptive intake.48 A hypothesis may be the varying oestrogen 
sensitivity of the different HCA subtypes (higher in I-HCA as com-
pared to H-HCA), but this has yet to be proven.21,49
Haemorrhage is the most frequent complication in HCA, and has 
been reported in up to 25% of cases.45 Not all patients are symptom-
atic, especially intratumoral haemorrhage may go unnoticed. When 
lifestyle changes are implemented, treatment is often not required 
as the hematoma will resorb over time and the tumour will regress. 
However, in some cases massive bleeding may occur resulting in 
intraparenchymal haemorrhage, subcapsular hematoma or even he-
moperitoneum caused by rupture of the liver capsule. When massive 
bleeding occurs patients may present with hemodynamically unsta-
ble conditions. In the acute phase, conservative management is jus-
tified when hemodynamic stabilization can be reached.50 In case of 
persistent hemodynamic instability or active bleeding, transarterial 
embolization (TAE) is the preferred management.51 Liver resection 
is not advisable in the acute phase as it is associated with increased 
morbidity and mortality.50,52
Pregnancy used to be discouraged in patients with unresected 
HCA, because of the risk of hormone induced growth and rupture 
during pregnancy. In 2004, a study was published reporting the mor-
tality risk of ruptured HCA during pregnancy: 44% for the mother 
and 38% for the foetus.53 The majority of cases included in this 
review dated from the 1970s and 1980s. However, in 2011 it was 
shown that a large number of patients who were diagnosed with 
HCA, already had been pregnant and had uneventful pregnancies.54 
This initiated a study that was recently published, assessing the risk 
of growth and haemorrhage of HCA <5 cm during pregnancy. In this 
study, growth occurred in a quarter of cases but no haemorrhage 
occurred.55 No subgroups at risk for growth could be identified in 
this cohort. Given the fairly high proportion of patients with growing 
HCA, close monitoring during pregnancy with ultrasound is recom-
mended, enabling an intervention in case of progressive growth.55 
Future research should focus on trying to identify subgroups at risk 
of pregnancy-related complications.
In addition, given the sensitivity of HCA to hormones in fertile 
women, a study was performed questioning whether surveillance 
of HCA is still required in post-menopausal women.56 The study 
showed that HCA become smaller after menopause and that routine 
follow-up of small HCA (<5 cm) is not required.56
When a patient is diagnosed with HCA, a great number of factors 
should be taken into account when deciding whether the patient 
should undergo a resection or whether a wait-and-see policy is legit-
imized. The most important patient related factors to be considered 
include sex, age and co-morbidity. For instance, resection is advised 
in men given the far higher risk of malignant transformation (esti-
mated 50% in men as compared to 5% in females).23,42,57 Additionally, 
although rare, resection may be advised in patients with HCA and 
hepatitis B or C infection, given the a priori higher risk of HCC. The 
key tumour factor that should be considered is the HCA subtype: 
patients with b-(I)HCA and sh-HCA are at greater risk of complica-
tions and therefore surgical resection is preferred. When malignancy 
is suspected on imaging a resection should be performed. A wait-
and-see policy is legitimized in H-HCA and I-HCA without ß-catenin 
mutation that show regression with lifestyle changes.
As for every type of liver surgery, the anatomical location of 
the tumour should be taken into account as well as the quality 
and volume of the future liver remnant. As a large number of pa-
tients with HCA are overweight or obese, the presence and degree 
of steatosis should be taken into account as these factors impact 
the perioperative complication- and mortality rates of liver re-
sections.58 A model combining all these factors would be an ideal 
solution. A decision curve analysis (DCA) is an example of a model 
requiring a binary decision, in our case this would be surgery ver-
sus wait-and-see. We would have to decide how many patients we 
would be willing to operate although they will not have tumour-re-
lated complications, to avoid one patient getting haemorrhage or 
malignant transformation. To perform such an analysis we would 
require detailed information on surgical complications in those 
treated with a resection and the incidence of malignant transfor-
mation and haemorrhage in those treated conservatively. A very 
large population would be needed to estimate the risks and ben-
efits of both treatment strategies. Unfortunately, considering the 
low incidence of HCA and the rare indications for surgery, it will 
be hard to realize a prospective study. Furthermore, the surgical 
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expertise will definitely play a major role in the outcome of such 
a study. Referring these patients to expert liver centres may offer 
the best-case scenario for diagnostic and surgical management at 
present.
7  | HOW TO TRE AT
Elective surgical resection is the gold standard in the treatment of 
patients with HCA. Resection of HCA can safely be performed with 
either an open or laparoscopic approach.59 Although laparoscopy 
may require more advanced surgical skills and is dependent on the 
size and location of the tumour, it also has great benefits as com-
pared to an open approach, including a reduction in blood loss and a 
shorter duration of hospital stay.60,61
Other treatment methods investigated for the treatment of HCA 
are transarterial embolization (TAE) and tumour ablation (either 
radiofrequent ablation or microwave ablation). TAE is a well-estab-
lished treatment to use for HCA showing acute haemorrhage with 
hemodynamic instability,51 but recent studies have also investigated 
its safety and efficacy in the elective treatment of non-haemorrhag-
ing HCA. TAE appears to be a safe and can lead to size reduction of 
HCA, although its effect is difficult to distinguish from the ongoing 
effect of cessation of oral contraceptives.62,63 Additionally, the ef-
fect TAE has on the risk of malignant transformation is still unclear. 
Tumour ablation might also be used in the treatment of HCA, but 
often multiple sessions are required and patients might still have 
residual HCA despite repetitive treatment.64 Both TAE and tumour 
ablation techniques may only be beneficial in patients with small le-
sions who are poor surgical candidates.11
Liver transplantation has been proposed as a treatment for pa-
tients with many widespread HCA (>10, liver adenomatosis). To date, 
this is no longer considered an indication for liver transplantation.57 
Liver transplantation is a major procedure and given the organ short-
age, it should be reserved for those with histological evidence of 
malignancy that cannot be treated with liver resection.65 The only 
patients with HCA that might be considered for liver transplanta-
tion are men with widespread nonresectable HCA and patients with 
glycogen storage disease and multiple progressing HCA at risk for 
malignant transformation.
8  | FINAL REMARKS
HCA may be considered a rare disease. The small number of pa-
tients and the limited epidemiological data pose challenges for 
research and the clinical development. It is preferable to treat pa-
tients with suspected HCA in high volume centres with combined 
expertise of liver surgeons, hepatologists, radiologists and (molec-
ular) pathologists. To optimize the validity and reliability of future 
research, it is important to collaborate in (inter)national multicen-
tre consortia to optimize our insights in diagnosis and treatment 
of this rare disease.
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